Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Sickle Cell Trait, Clinical Practice (Health Services and Quality), Hemoglobinopathies, Diversity, Equity, and Inclusion (DEI), Education, Diseases
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Sickle Cell Trait, Clinical Practice (Health Services and Quality), Hemoglobinopathies, Diversity, Equity, and Inclusion (DEI), Education, Diseases
Sunday, December 8, 2024: 9:30 AM-11:00 AM
Room 33
(San Diego Convention Center)
Lecture Title:
The Role of Quality Metrics in Demonstrating Value of Your Sickle Cell Disease Center
Co-chairs:
Sophie Lanzkron, MD, Sidney Kimmel College of Medicine, Thomas Jefferson University
and
Cecelia Calhoun, MD, MBA, MPH, Yale New Haven Hospital
Disclosures:
Lanzkron: HRSA: Research Funding; PCORI: Research Funding; CSL-Behring: Research Funding; GBT: Research Funding; Takeda: Research Funding; GMI: Consultancy; Agios: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy; Merck: Consultancy; Pfizer: Consultancy; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; Bluebird BIo: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other: Stock in Family trust; Teva: Other: Stock in Family trust.
To ensure high-quality care for patients with sickle cell disease (SCD), it is imperative that providers and SCD care leaders have the tools to establish comprehensive clinical care centers for patients with SCD. Over the last several years, ASH has developed a program and blueprint for the creation of sickle cell disease centers. This special interest session is designed to help sickle cell disease care centers understand the development of CMS quality metrics and how to leverage these metrics to support delivery of high-quality care.
See more of: Special-Interest Sessions